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Jeffrey S. Gale, MD, FRCSC b; Sanjay Sharma, MSc, FRCSC b,1AbstractPurpose: To study the effect of intravitreal ranibizumab on idiopathic epiretinal membranes (ERMs).
Methods: A retrospective cohort study on a consecutive series of ranibizumab intravitreal injections for epiretinal membranes was
performed. Four cases were identified by reviewing a claims database linked to electronic medical records. All patients received a
total of three 0.05 mg/0.05 ml ranibizumab intravitreal injections at a monthly interval. The primary outcome measure was the final
best-corrected visual acuity (BCVA) at the end of the injection series, and the final central macular thickness (CMT).
Results: All four patients completed 3 months follow-up after the last ranibizumab injection. The mean baseline CMT was
509 microns (SD = 111). A trend was noticed for reduction in CMT (D = 41 microns) P = 0.08. Three patients improved by one line
in their BCVA. The remaining patient maintained the same BCVA. No complications were noted.
Conclusion: In this study, intravitreal injection of ranibizumab marginally reduced retinal thickness in four patients with minimal
improvement in visual acuity. No safety concerns were noticed. Further basic science and clinical studies may be warranted to
assess the role of vascular endothelial growth factor and the effect of ranibizumab on idiopathic epiretinal membranes.
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Epiretinal membrane (ERM) is a glial proliferation on the
surface of the retina along the internal limiting membrane
that may cause visual distortion, blurred vision, or decreased
visual acuity when present in the macular area.1 It can be idi-
opathic in origin, or a consequence of prior intraocular sur-
gery, inflammation, retinal vasculopathy, or trauma.1,2
Surgical removal of epiretinal membrane by means of pars
plana vitrectomy is usually performed in visually symptomatic
patients with good post-operative visual outcomes, but manysurgeons implement a minimum visual acuity of 20/5020/60
as a cutoff point for performing surgery.3,4 This threshold for
surgery leaves no therapeutic option for those with symp-
tomatic ERM and visual acuity of 20/40 or better. In addition,
some patients who are symptomatic with advanced ERM
might decline vitrectomy or are poor surgical candidates.
ERM is a progressive condition; between 10–37% of eyes
with ERMs will demonstrate a decrease in visual acuity over
three years.5,6
Vascular Endothelial Growth Factor (VEGF) is a cytokine in-
volved in multiple physiological processes, of clinical signifi-e:
al.com
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than the vascular endothelium.7,8 Example of such processes
include dendritic cell differentiation and function,9 neural cell
survival,10 and trophic support of choriocapillaris.11 Immuno-
histochemical studies have demonstrated VEGF and its
receptors within both vascular and avascular ERM7 with local-
ization to the glial cells and retinal pigment epithelial (RPE)
cells of the ERM. Angiogenesis and VEGF expression do
not necessarily correlate when it comes to ERM prolifera-
tion.8 Thus VEGF, in addition to being a powerful angiogenic
and vascular permeability factor,12 may play an important
role in the stimulation of ERM formation.
Ranibizumab (Lucentis, Genentech, San Francisco, CA) has
shown significant safety and efficacy in phase III trials in the
treatment of age-related macular degeneration by inhibiting
biologically active VEGF-A isoforms as proven by many ran-
domized clinical trials.13,14 Given the few alternatives for
symptomatic ERM and the possibility that VEGF may play a
role in the pathogenesis of ERM, we conducted a retrospec-
tive analysis of consecutive cases that received ranibizumab
and looked into its effects on idiopathic ERM.Methods
We reviewed an administrative claims database to identify
patients with ERM who received ranibizumab. Four consecu-
tive cases were identified. In all four cases, patients had a thor-
ough informed consent performed and understood that the
treatment they were to receive was off-label for this indication
given their symptoms and as an alternative for those who re-
fused surgical intervention. Patients underwent routine bestFigure 1. Optical coherence tomography (OCT) for Patient 1 showing reducti
(left, before treatment; right, three months after third injection). Note the discorrected visual acuity (BCVA) testing and intraocular pres-
sure measurement, fundus fluorescein angiography, and opti-
cal coherence tomography (OCT) scans with Cirrus HD-OCT
(Carl Zeiss Meditec, Dublin, California) both before and one
month after the injection series. We used the built-in anatomic
tracking software to measure the same central macular loca-
tion at follow-up. Intravitreal injection of 0.5 mg/0.05 ml rani-
bizumab was done via a 30-gauge needle inserted 3.5 mm
from the limbus, administered monthly for three months un-
der sterile conditions using topical 5% povidone-iodine drops
and 10% povidone-iodine lid scrub. Topical xylocaine gel to
anesthetize the eye and a sterile lid speculum were used in
the process. All patients were followed for at least three
months after the last injection. The outcome measures were
BCVA, and thickness of the central area with a 1 mm diameter
on OCT – central macular thickness – (CMT). The approval of
the Research Ethics Board was obtained for this study.Results
Four patients, two females and two males, with a mean
age of 72.5 years (range: 60–84 years) received intravitreal
ranibizumab injection for idiopathic ERM. Prior to starting
these injections, their average CMT was 509 ± 111 microns
(mean ± SD). Their mean BCVA (logMAR) was 0.62 ± 0.27
[Snellen equivalent, 20/80]. At the end of the third month
follow-up after the third injection of ranibizumab, the mean
CMT was 468.75 ± 86.27 microns (Figs. 1 and 2). Mean BCVA
(logMAR) was 0.56 ± 0.22 [Snellen equivalent, 20/70]. No
complications were encountered from injections or during
the three month follow-up. Table 1 summarizes the pre-andon in central macular thickness after ranibizumab injections by 45 microns
appearance of the central macular cyst.
Figure 2. OCT images showing reduction of CMT by 82 microns and shrinking of cystoid spaces in Patient 3.
Table 1. Summary of cases.
Sex/Age(yrs) CMT BCVA
Pre-injection Post-injection Pre-injection Post-injection
Patient 1 Male/68 558 513 6/24 6/21
Patient 2 Female/78 359 344 6/15 6/15
Patient 3 Male/84 619 537 6/60 6/45
Patient 4 Female/60 500 481 6/18 6/15
CMT = Central macular thickness, BCVA = Best corrected visual acuity.
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central macular thickness (mean D in CMT = 41 mi-
crons ± 24.91, P = 0.08).Discussion
Based on immunopathologic studies, VEGF may play an
important role in the development of ERM.7,8 In our present
study, we evaluated the CMT and BCVA for patients with idi-
opathic ERM before and after intravitreal injection of rani-
bizumab. We found a trend in the reduction in CMT of
patients with idiopathic ERM after injection of three doses
of ranibizumab. This reduction appears to be related to a de-
crease in macular edema, presumably related to rani-
bizumab’s effect on vascular permeability. The membrane
was still visible in all cases and showed no appreciable
change at the resolution level of spectral domain-OCT. BCVA
improved by one line in three patients and was maintained at
the same level in the remaining patient. No ocular or systemic
adverse events were noted.There are no published data evaluating the effect of rani-
bizumab on idiopathic ERMs. However, Luttrull and Spink15
showed that anti-VEGF injection for eyes with age-related
subfoveal neovascularization and ERM followed by surgical
removal of the ERM might offer further improvement in visual
acuity. Kon-Jara concluded that the presence of ERM with
wet age-related macular degeneration results in poorer visual
outcomes when treated with ranibizumab (Kon-Jara V, Chau-
dhry N, Tabandeh H, et al. Visual and Anatomic Outcomes of
Intravitreal Anti-VEGF Therapy for Exudative AMD with Sig-
nificant Epiretinal Membrane. Poster presented at: American
Society of Retina Specialists Annual Meeting, 2010; Vancou-
ver). Watanabe et al.16 demonstrated a correlation between
metamorphopsia detected in ERMs and the actual thickness
on OCT. Of note, Kuiper et al.17 reported that anti-VEGF
treatment could alter the angiogenic signal into a pro-fibrotic
one by altering the balance between connective tissue
growth factor (CTGF) and VEGF in diabetic retinas. A similar
mechanism may explain fibrosis and contraction after
anti-VEGF administration for retinopathy of prematurity.18
Idiopathic ERMs are usually avascular membranes, thus we
82 M.A. Abouammoh et al.presume that they are exempted from this fibrotic response
to anti-VEGF.
Conclusion
In this small case series, we report that ranibizumab may
have a role in treating ERM by reducing associated macular
edema. The mean change in CMT approached statistical sig-
nificance, and there was improvement in visual acuity in three
out of four patients, although a placebo effect cannot be ru-
led out. The conclusions of this study are preliminary given
the small sample size. We believe a larger, prospective clini-
cal trial is warranted to evaluate ranibizumab for the treat-
ment of idiopathic ERM. Currently the lucentis for epiretinal
membrane (LERM) study is ongoing.19 Results of the study
should provide more insight into the role of ranibizumab in
treating ERM.
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